Skip to main content

Non-erosive Reflux Disease

5
Pipeline Programs
3
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

AstraZeneca
PRILOSECApproved
omeprazole
AstraZeneca
oral1989
3M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
1
OmeprazolePhase 3Small Molecule1 trial
OmeprazolePhase 3Small Molecule1 trial
Active Trials
NCT00259051Completed40Est. Aug 2004
NCT00259077Completed270Est. Jul 2004
Shandong Luoxin Pharmaceutical
1 program
1
LXI-15028Phase 31 trial
Active Trials
NCT03591653Completed291Est. Nov 2019
Yooyoung Pharmaceutical
Yooyoung PharmaceuticalKorea - Jincheon
1 program
1
YYD601 20mgPhase 31 trial
Active Trials
NCT03967886Completed170Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Yooyoung PharmaceuticalYYD601 20mg
Shandong Luoxin PharmaceuticalLXI-15028
AstraZenecaOmeprazole
AstraZenecaOmeprazole

Clinical Trials (4)

Total enrollment: 771 patients across 4 trials

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Start: Apr 2019Est. completion: May 2020170 patients
Phase 3Completed

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks

Start: Oct 2018Est. completion: Nov 2019291 patients
Phase 3Completed

A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Start: Jan 2004Est. completion: Aug 200440 patients
Phase 3Completed

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Start: Oct 2003Est. completion: Jul 2004270 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.